In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Pharmaceutical
The long-rumored acquisition of US biotech Seagen was finally announced in March, albeit it was not long-time suitor Merck & Co behind the deal, but rather fellow US pharma giant Pfizer. 4 April 2023
Pharmaceutical
Spanish epigenetics firm Oryzon Genomics has announced encouraging results from a planned interim analysis of the Phase IIb PORTICO study. 4 April 2023
Biotechnology
Wuppertal, Germany-based infectious disease drug developer AiCuris Anti-infective Cures today announced the appointment of Larry Edwards as chief executive (CEO), effective April 1, 2023. 4 April 2023
Biotechnology
Privately-held US precision oncology company Scorpion Therapeutics has announced a deal with French drugmaker Pierre Fabre. 4 April 2023
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Padcev (enfortumab vedotin-ejfv) with Keytruda (pembrolizumab), with the decision coming ahead of anticipated date of April 21. 4 April 2023
Pharmaceutical
Dermatology company Botanix Pharmaceuticals has safely navigated the US Food and Drug Administration (FDA) mid-cycle review with sofpironium bromide. 4 April 2023
Biotechnology
French drugmaker Sanofi has announced the publication of data from studies on its hemophilia candidate fitusiran in two medical journals. 4 April 2023
Pharmaceutical
The administrators of the USA’s public insurance scheme, Medicare, are getting ready to implement the measures included in the Inflation Reduction Act. 4 April 2023
Biotechnology
OncoSec Medical closed down almost 50% on Monday and fell a further 6% to $1.22 pre-market today, after the company announced primary endpoint data from the Phase II KEYNOTE-695 clinical trial that missed its goals. 4 April 2023
Biotechnology
Austrian drug discovery company Quantro Therapeutics has appointed Dr Michael Bauer as the firm’s chief executive (CEO), effective May 1, 2023. 4 April 2023
Biotechnology
The late-breaking data on AbbVie’s (NYSE: ABBV) blocker Skyrizi (risankizumab) in plaque psoriasis (PsO) that was presented at the recently concluded American Academy of Dermatology (AAD) Annual Meeting is expected to help Skyrizi’s positioning in the crowded PsO biologics space. 4 April 2023
Biotechnology
Continuing to invest the massive profits generated from its COVID-19 vaccine Comirnaty success, German biotech BioNTech has signed up for another oncology collaboration. 3 April 2023
Pharmaceutical
Shares in Sweden’s Asarina Pharma looked set to close more than 2% higher based on results from its Phase IIa study of the endogenous neurosteroid sepranolone for the treatment of Tourette syndrome. 3 April 2023
Biotechnology
US drugmaker Eli Lilly has again shown that Eisai and Biogen are not the only players in town in the Alzheimer’s space. 3 April 2023
Pharmaceutical
Japanese drugmaker Eisai (TYO: 4523) has entered into an agreement with the National Cancer Center to collaborate on investigator-initiated clinical research for the EZH2 inhibitor Tazverik (tazemetostat hydrobromide) based on “Patient-Proposed Healthcare Services” system, which will be conducted by the National Cancer Center Hospital. 3 April 2023
Pharmaceutical
Karim Mikhail is to resign as president and chief executive of Amarin Corp, the Ireland-headquartered fish oil-based heart drug specialist, according to a US Securities and Exchange Commission filing. 3 April 2023
Biosimilars
Germany’s STADA Arzneimittel and Sweden’s Xbrane Biopharma are introducing Ximluci (ranibizumab) in several European countries to offer European ophthalmologists and their patients a cost-effective option to treat visual impairment, including neovascular or wet age-related macular degeneration (AMD). 3 April 2023
Biotechnology
French oncology focussed biotech firm Innate Pharma’s shares were up 16.6% at 3.12 euros in early trading today, as it revealed an exclusive license agreement with Japan’s Takeda (TYO: 4502) 3 April 2023
Pharmaceutical
The COVID-19 pandemic brought into the spotlight, at European level and particularly in Greece, the gaps in the national health systems, which are mainly due to underfunding and long-standing distortions, commented the Hellenic Association of Pharmaceutical Companies (SFEE). 3 April 2023
Pharmaceutical
The Irish Minister of International Development and Diaspora, Sean Fleming, visited Brazil’s research institute Fiocruz last month to discuss partnership projects between the country and Fiocruz. 3 April 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze